MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Quanterix Corp

Fermé

SecteurSoins de santé

7.39 -6.46

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.36

Max

7.61

Chiffres clés

By Trading Economics

Revenu

-3.5M

-34M

Ventes

16M

40M

Marge bénéficiaire

-83.479

Employés

471

EBITDA

5.7M

-31M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+1.35% upside

Dividendes

By Dow Jones

Prochains Résultats

16 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

106M

344M

Ouverture précédente

13.85

Clôture précédente

7.39

Sentiment de l'Actualité

By Acuity

17%

83%

14 / 361 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Neutral Evidence

Quanterix Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 janv. 2026, 23:29 UTC

Actions en Tendance

Stocks to Watch: Atossa Therapeutics, Union Pacific

17 janv. 2026, 15:06 UTC

Acquisitions, Fusions, Rachats

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

17 janv. 2026, 10:30 UTC

Résultats

Supersize CEO Pay Packages Aren't Paying Off for Shareholders -- WSJ

17 janv. 2026, 03:10 UTC

Acquisitions, Fusions, Rachats

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

16 janv. 2026, 22:48 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 janv. 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 janv. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Auto & Transport Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 janv. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 janv. 2026, 21:48 UTC

Market Talk
Acquisitions, Fusions, Rachats

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 janv. 2026, 21:41 UTC

Market Talk
Acquisitions, Fusions, Rachats

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 janv. 2026, 21:38 UTC

Acquisitions, Fusions, Rachats

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 janv. 2026, 20:44 UTC

Résultats

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 janv. 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 janv. 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 janv. 2026, 19:12 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 janv. 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 janv. 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 janv. 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 janv. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 janv. 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparaison

Variation de prix

Quanterix Corp prévision

Objectif de Prix

By TipRanks

1.35% hausse

Prévisions sur 12 Mois

Moyen 7.5 USD  1.35%

Haut 8 USD

Bas 7 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

2 ratings

0

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

5.34 / 6.015Support & Résistance

Court Terme

Neutral Evidence

Moyen Terme

Bullish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

14 / 361Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat